Agonistic anti-tumor necrosis factor receptor 2 antibodies
AssigneeThe General Hospital Corporation
InventorDenise L. Faustman
Life of this patent
Estimating the term…
Abstract
The invention provides agonistic TNFR2 antibodies and antigen-binding fragments thereof and encompasses the use of these antibodies as therapeutics to promote the proliferation of regulatory T cells (T-reg) for the treatment of immunological diseases. Antibodies of the invention can be used to potentiate the T-reg-mediated deactivation of self- and allergen-reactive T- and B-lymphocytes, and can thus be used to treat a wide variety of indications, including autoimmune diseases, allergic reactions, asthma, graft-versus-host disease, and allograft rejection, among others.
Claims13
An antibody or antigen-binding fragment thereof that specifically binds human tumor necrosis factor receptor 2 (TNFR2) comprising:
- (a) means for binding an epitope within human TNFR2 bound by antibody 8E6.D1 (ATCC® accession number PTA-127418);
- and
- (b) an Fc region,
- wherein the antibody or antigen-binding fragment thereof does not bind an epitope within human TNFR2 comprising amino acids 142-146 of SEQ ID NO:
- 366.
An antibody or antigen-binding fragment thereof that specifically binds human TNFR2, wherein the antibody or antigen-binding fragment thereof is antibody 8E6.D1 (ATCC® accession number PTA-127418), wherein the antibody or antigen-binding fragment thereof specifically binds:
- (a) an epitope within human TNFR2 comprising amino acids 56-60 of SEQ ID NO:
- 366;
- and/or
- (b) a polypeptide having the amino acid sequence of SEQ ID NO:
- 346 or 367;
- and wherein the antibody or antigen-binding fragment thereof does not bind an epitope within human TNFR2 comprising amino acids 142-146 of SEQ ID NO:
- 366.
Dependencies are inferred from the claim text.